MK-2140-006: A trial testing zilovertamab vedotin in people with selected B-cell lymphoma

A phase 2 trial assessing the medication zilovertamab vedotin (MK-2140) in adults with select relapsed or refractory B-cell lymphomas.

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT05458297

Trial aim and background  

The aim of this trial is to find out how safe and well tolerated the medication zilovertamab vedotin (MK-2140) is when given alone or in combination with other medications in patients with select relapsed or refractory B-cell lymphomas. This includes mantle cell lymphoma (MCL), Richter’s transformation lymphoma (RTL), follicular lymphoma (FL) and chronic lymphocytic lymphoma (CLL). 

It will also aim to test the response rate to MK-2140 as both a monotherapy and in combination with other medications.

Who can enter 

Adults with a confirmed B cell malignancy (including MCL, FL, RTL and CLL) who have failed to respond to two previous systemic treatments may be eligible for this trial.

Locations 

Recruitment is taking place in the following UK locations:

  • The Royal Cornwall Hospital, Truro, Cornwall
  • University College London Hospital, London
  • The Churchill Hospital, Oxford, Oxfordshire

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT05458297

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.